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There is a growing need to enhance our capabilities in medical and environmental diagnostics. Synthetic biologists have begun to focus their
biomolecular engineering approaches toward this goal, offering promising results that could lead to the development of new classes of
inexpensive, rapidly deployable diagnostics. Many conventional diagnostics rely on antibody-based platforms that, although exquisitely
sensitive, are slow and costly to generate and cannot readily confront rapidly emerging pathogens or be applied to orphan diseases. Synthetic
biology, with its rational and short design-to-production cycles, has the potential to overcome many of these limitations. Synthetic biology
devices, such as engineered gene circuits, bring new capabilities to molecular diagnostics, expanding the molecular detection palette, creating
dynamic sensors, and untethering reactions from laboratory equipment. The field is also beginning to move toward in vivo diagnostics, which
could provide near real-time surveillance of multiple pathological conditions. Here, we describe current efforts in synthetic biology, focusing on
the translation of promising technologies into pragmatic diagnostic tools and platforms.
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Synthetic biology employs a forward-engi-
neering approach to create new molecular
function. In the field’s earliest stages, engi-
neering principles guided the design and con-
struction of synthetic gene regulatory circuits,
such as toggle switches and ring oscillators
(1, 2), which quickly led to the develop-
ment of logic, sensor, counter, and timer
elements (3). These capabilities continue
to grow in complexity and now include
biomolecular circuits that can interrogate
both intra- and intercellular spaces and,
in response, direct downstream activity
of other engineered components, as well
as endogenous cellular elements. Although
there is not a clear consensus regarding a
definition of the boundaries of synthetic
biology, it is widely accepted that squarely
within them is the aspiration to use syn-
thetic circuitry and other engineered com-
ponents to create novel functions inside
cells. In the context of diagnostics, syn-
thetic biology design efforts are typically
focused on building sensors that are cou-
pled to a measurable output. These circuits
are the outcome of the engineered assembly of
natural molecular components, which have
been rewarded with survival for their func-
tional performance through eons of natural
selection. Biology is enriched with an incred-
ible molecular diversity of sensors and regula-
tors that helpmaintain organismhomeostasis,
find resources, and avoid deleterious stresses.
Synthetic biologists are beginning to draw
on this diversity of sensors and regulatory
elements, incorporating them into gene net-
works and applying their own design crite-
ria of selection for use within novel synthetic
architectures. Here, we describe how this
rationale is being applied to confront the
growing need for novel diagnostic tools
and capabilities.
Whole-Cell Biosensing
Hybrid Devices. Synthetic biology was rec-
ognized early on as an opportunity to engi-
neer organisms that could serve as whole-cell
biosensors in what may be viewed as an ex-
tension of the use of animal sentinels for
environmental sensing throughout history.
Examples of the latter include caged canaries
warning of toxic gases in coal mines, the
centuries-old practice of using hogs to locate
rare truffles, or training dogs to detect illicit
materials, explosives, or even cancer (4). In
the years preceding the emergence of syn-
thetic biology, animal sentinels were scaled
down to the essential unit of life: the living
cell. Early cell-based biosensors were a phys-
ical merger between single-cell organisms and
hardware components that could transduce
biochemical signals into a measurable elec-
tronic output. Mounted onto electrodes, the
cells functioned as the sensor component of
the larger detector. In one example, photosyn-
thetic cyanobacteria were used as biocatalysts
that reduced an electrochemical mediator,
[Fe(CN)6]
3-/4-, which then donated an electron
to the electrode, producing a steady current
flow that correlated to photosynthetic activity
(5). This activity and the ensuing current were
disrupted by herbicides and, therefore, could
report their presence in testedwater. In another
example,Zymomonasmobiliswas immobilized
on a pH electrode, and its native glucose–
fructosemetabolic activity was used tomeasure
sugar levels via hydrogen ion production (6).
These native cell-based technologies car-
ried important advantages over abiotic sen-
sors based on purified antibodies or nucleic
acid hybridization, including lower cost, im-
proved stability, and the capacity to generate
higher biocatalytic activity (7, 8). However,
whereas these early biosensing devices were
remarkable, they suffered from poor selec-
tivity and interference from culturing condi-
tions (9). As the genetic modification of
microorganisms became more practical, syn-
thetic whole-cell biosensors were engineered
such that the microorganism encompassed
both purpose-built analyte sensors and signal
output components. Thus, rather than being
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constrained by naturally evolved systems, the
organism itself became the target of engi-
neering efforts (10). Designer circuits tuned
for specific molecular recognition, rather than
a general effect on host physiology, provided
a significant step forward for biomolecular
selectivity. In many early embodiments,
the signaling element relied on genetically
introducing luciferase gene cassettes for bio-
luminescent reporting. For instance, by fus-
ing the Vibrio fisheri luxCDABE cassette to a
naphthalene degradation operon in Pseudo-
monas fluorescens, these living biosensors
could sense naphthalene and salicylate bio-
availability and produce a bioluminescent
response (11). Over time, bacterial strains
were genetically modified to detect arsenic in
natural water resources (12), as well as fam-
ilies of other analytes, including hydrocarbon
pollutants, sugars, heavy metals, and antibi-
otics (13).
The integration of living cells with ma-
chines was a trend that persisted through
the early days of synthetic biology, with the
coupling of genetically engineered whole-cell
sensors to electrochemical, optical, or me-
chanical transducers. Compact and portable
hybrid devices incorporating whole-cell sen-
sors directly mounted onto integrated circuits
enabled bioluminescent quantification out-
side of the laboratory (9, 14). Other examples
include devices that mimicked natural bio-
films by using protective cellular encapsula-
tion in polymers, or whole-cell biosensing
arrays for multiplexing (9, 15, 16). The trend
of hybrid devices has mostly been abandoned
for the convenience of plate readers because
data can be collected using this platform in
an automated and high-throughput fashion.
Interestingly, this convenience may have
had the unintended consequence of drawing
synthetic biology toward laboratory applica-
tions rather than deployable tools. However,
as efforts move toward pragmatic applica-
tions, especially those that may be applied in
the field, the revitalized integration of com-
panion electronics with engineered cells may
be an important path forward.
RNA-Based Biosensing in Living Cells. As
synthetic biology has matured, increasing
gene circuit complexity has allowed for
greater sensitivity and reporter tunability
(17). We now have the potential to expand
biosensing to metabolites and disease-specific
RNAs, including sequences imparting drug
resistance. Like proteins, RNA molecules
can serve as biological catalysts and genetic
regulatory elements. Examples of the latter
occur naturally (18–20) and have, more re-
cently, become the target of engineering
efforts to harness RNA-based sensing through
riboregulators and Spinach RNA for small
molecules and target RNA sequences (21–25).
RNA sensing for diagnostics recently took a
leap forward with the development of a new
class of RNA sensors called toehold switches
(26). Until this point, riboregulators relied on
the sequestration of the ribosomal binding
site (RBS), via a cis-repression sequence, to
control the translation of the downstream
mRNA (Fig. 1A). In the presence of a higher
affinity RNA molecule (the transactivator),
the RBS is exposed and translation ensues.
Although useful, riboregulators are limited
for diagnostic applications because the
transactivator must share sequence con-
servation with the RBS, which is not a
distinguishing feature of real-world mRNA
sequences. Green et al. (26) resolved this
constraint by adding a “toehold” for trigger
RNA binding and positioning the RBS in
a loop region of an RNA hairpin, which
prevents ribosomal binding and reporter
translation while eliminating the need for
sequence conservation between the trans-
activating component and the RBS (Fig. 1B).
Translation begins only when the trigger
RNA binds the toehold, which unzips the
hairpin into a linear state. This approach
was further extended to the detection of full-
length mRNA in living cells, highlighting
the potential toward intracellular RNA di-
agnostics. Importantly, toehold-based sen-
sors can be rationally designed de novo
by placing the complement of the target
sequence in the 5′ region of the toehold.
Using these toehold sensors, bacteria were
programmed to detect both short synthetic
RNAs and full-length endogenous mRNAs
within the cellular environment.
Such RNA-sensing technology has great
diagnostic potential; however, while confined
within the structure of the bacterial cell, its
accessibility to target RNA in clinical samples
is limited and, therein, its range of applica-
tion, as well. This example and whole-cell
biosensors in general are also inherently
bound to biosafety concerns with regard to
the release of genetically modified microor-
ganisms into certain environments. There-
fore, one of the challenges and opportunities
that synthetic biology faces in the development
of deployable diagnostics is to circumvent
such limitations when possible. Conse-
quently, focus has recently been trained on
practical approaches for hosting these pow-
erful tools outside of the cell. As we discuss
below, there are new technologies that have
successfully brought the rational design of
synthetic biology to in vitro diagnostics.
In Vitro Diagnostics
Phage-Based Diagnostics. Although con-
ventional antibody-based diagnostics have, in
many ways, met the growing need for in vitro
diagnostic tools for clinical and global health,
the rational design principles of synthetic
biology promise a revolution toward the
development of new diagnostic tests for a
Fig. 1. RNA-based biosensors and synthetic biology platforms for in vitro diagnostics. (A) Conventional ribor-
egulators inhibit the translation of mRNA from the start codon (AUG) by sequestering the RBS through a cis-repression
sequence (Cis), which is relieved in the presence of the transactivator RNA (taRNA). (B) In the toehold switch model,
the RBS is located in a hairpin loop within the repressed RNA’s 5′ untranslated region and a toehold is added to the
5′ end. This alternative regulatory RNA structure allows for a much larger RNA sequence space to be detected. (C ) In
vitro phage-based diagnostics rely on specific recognition of target bacterial species by engineered phage particles.
Once the phage has bound, the engineered phage genome is injected into the targeted cells, where the reporter gene
is expressed (i.e., luciferase; yellow circles) and phage replicate. (D) Paper-based systems are assembled by freeze-drying a
diagnostic gene network and a cell-free coupled transcription/translation system into paper or other porous materials. The
gene circuit becomes active when rehydrated with the test sample, containing target RNAs or small molecules.
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fraction of the cost and time. Engineered
bacteriophage are leading the advance into
this space. These bacterial viruses harbor
natural specificity to a wide range of bac-
terial pathogens and can be used to trans-
form target bacteria into factories for
reporter molecules. In diagnostic applica-
tions, the presence of the correct bacterial
surface epitope serves as a conditional in-
put that regulates the transfer of the engi-
neered phage genome into the bacteria,
leading to luciferase or other reporter gene
expression (Fig. 1C). Phage binding speci-
ficity can be further optimized through
directed evolution, allowing for highly
selective reporting even within complex
bacterial cultures, prompting many groups
to engineer synthetic phage platforms that
can identify within minutes contamination
by specific bacterial strains (27, 28). Phage
also have the advantage of being inexpensive
to manufacture because the material for 107
different tests could theoretically be gener-
ated from a 100-L fermenter (29). Using
such techniques, there are now commercially
approved products for microbial detection in
industrial settings, and clinical applications
have been demonstrated as well (28). One
compelling example is based on an engi-
neered variant of the CDC plague diagnostic
phage, ɸA1122, for Yersinia pestis, the etio-
logic agent of the bubonic plague (29, 30). The
bacteria can be detected through expression of
a phage-vectored bioluminescence reporter
within 40 min in liquid culture or 120 min in
human serum. Other clinical demonstrations
include reporter systems for Bacillus anthracis
(31) and Mycobacterium tuberculosis identifi-
cation. These methods can be combined with
drug treatment to gather drug susceptibility
data along with species identification (29, 32).
Due to limited bacterial concentrations in test
samples, an enrichment stage is sometimes
required that, in the future, could perhaps be
remedied by low-cost microfluidics coupled
with a pathogen capture technology, such as
opsonin-coated beads that recognize the car-
bohydrate pattern on many clinically relevant
bacteria (33). This approach would also allow
for the removal of reporter-quenching con-
taminants, like hemoglobin, and delivery of
optimal medium for phage infection (34).
Paper-Based Synthetic Gene Networks.
A new concept takes in vitro synthetic bi-
ology a step further by completely removing
the cellular context and putting synthetic
gene circuits on paper (Fig. 1D) (35). In this
approach, commercially available cell-free
transcription/translation systems (bacterial or
mammalian) are freeze-dried onto paper or
other porous substrates to create poised
genetic regulatory networks that are stable for
long-term storage at room temperature and
are activated by rehydration. This work fol-
lows on other efforts in cell-free synthetic
biology, which have provided important
dynamic and mechanistic insight on gene
regulatory networks and allowed for rapid
“build-test” cycles for prototyping engineered
gene circuits and biomanufacturing pathways
(36–41). The in vitro nature of these systems
resolves the challenge faced by cell-based
approaches of importing biomolecular com-
ponents into the intracellular space, making
these cell-free environments easily modified
and excellent platforms for engineering.
The paper-based synthetic biology plat-
form provides a mode for safe and sterile
deployment of engineered gene circuits and
was demonstrated by incorporating toehold
switches and other circuit designs, exhibiting
small-molecule and RNA actuation. Impor-
tantly, the platform was also used to host
completely abiotic gene-based sensors for
glucose and mRNAs, including diagnostic
assays for four antibiotic resistance genes and
24 Ebola sensors (35). The Ebola sensors
could distinguish between Sudan and Zaire
strains and were developed in under 12 h for
a cost of just over $20 per sensor, a time and
cost regime that compares very favorably
with antibody-based diagnostics. In addition
to fluorescent reporter output, these sensors
were designed to produce enzymes that
generated color changes visible to the naked
eye, a necessary feature for low-resource en-
vironments lacking technical infrastructure.
Similar to early whole-cell synthetic biology
demonstrations, the paper-based reactions
were merged with custom, low-cost elec-
tronics for quantification and automation of
diagnostic reactions in the field.
After these proof-of-concept demonstra-
tions, several challenges remain for the
practical implementation of paper-based di-
agnostics, including meeting the detection
thresholds required for field use. To over-
come this challenge, amplification strategies
for incoming molecular signals (RNA/DNA)
could be adopted from other applications (33,
42). Using such platforms, both pathogen
identification and the recovery of other clin-
ically relevant data could be achieved, such as
surveillance of neuraminidase and hemag-
glutinin composition in seasonal variants of
influenza, allowing for early antiviral in-
tervention. Toehold-based sensors promise to
play a prominent role in a variety of di-
agnostic applications (26), but there are also
many other technologies and approaches
in development that could be paired with
the paper-based platform, including directed
evolution schemes, prospecting for naturally
occurring transcription factors, and the ra-
tional design of small-molecule sensors for
the detection of metabolites, hormones, or
drugs in patient samples (13, 43–45). Also, a
recently developed protocol has streamlined
the production of cell-free systems, enabling
synthetic biologists to generate tailored bio-
chemistry (46). An intriguing example could
be to develop systems in which the gene
circuit product is degraded in a targeted
manner, sparing the translational machinery
and allowing repetitive analyte tracking (47,
48). Incorporating transcription-only gene
circuits would result in simpler and faster
systems. These systems could include using
fluorescent Spinach RNA as a direct gene
circuit reporter, Spinach RNA sensors that
activate in the presence of their programmed
target molecule, and Spinach.ST RNA for
the detection of DNA and RNA sequences
(21, 22, 24).
In Vivo Diagnostics
As detailed above, one of the aims of syn-
thetic biology has been the engineering of
organisms to sense the environment. This
goal is now being extended to the mamma-
lian in vivo environment and also the engi-
neering of mammalian cells. As the expertise
of modeling and implementing synthetic
circuits has grown, so has the practicality
of using engineered cells (both microbial
and mammalian cells) as in vivo biosensors.
Circuits with simple logic operations have
been expanded into networks with complex
integrative logic and memory, which can
be used for this purpose. In the near term,
in vivo diagnostics hold great promise as
research tools to gain better understanding of
disease and host-response in situ and, going
forward, could be a powerful means for near
real-time monitoring of a wide range of
medical conditions. It is important to note
that, although there is a difference in the
nature of biosafety concerns related to the use
of genetically modified whole-cell biosensors
in the environment, there are also clear safety
concerns that need to be meticulously ex-
amined for the use of engineered cells for
in vivo diagnostics and therapeutics.
Bacterial Cell Hosts. In early efforts to de-
velop bio-based counting andmemory storage,
synthetic circuits were devised in Escherichia
coli (E. coli) using riboregulator or recombi-
nase designs (30). In the first of these archi-
tectures, sequential inducer pulses were
counted using riboregulator-mediated trans-
lational repression of T7 polymerase
(T7 RNAP) and a reporter transcript.
In the latter, recombinase cascades were
strung together, with each pulse “flipping”
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an invertase unit, leading to the expression
of the next recombinase in line and ending
with reporter gene expression. These mod-
els gave rise to the notion that in vivo en-
vironmental cues could drive memory units,
transforming bacterial host cells into di-
agnostic indicators for recording exposure
events. One possible use could be the non-
destructive interrogation of the human gut
microbiome, which is intertwined with
health, metabolism, and a growing list of
disease states or conditions (49). To this end,
E. coli were programmed to serve as “living
diagnostics” and report environmental sig-
nals in the mouse gut (Fig. 2E) (50). This
concept was accomplished by implanting the
bacteria with a memory element based on
the phage lambda cI/cro genetic switch (51).
A companion trigger element could detect
anhydrotetracycline (ATc) (dosed into the
mice’s drinking water) and switch a lacZ
reporting unit within the memory circuit to a
stable “on” state, recording the event for re-
trieval from fecal samples and interpretation.
Thinking to the future, sentinel bacteria could
reside in the guts of soldiers or aid workers
and serve as short-term “medical records,”
alerting on the time and scale of contamina-
tion or pathogen infection. Such in vivo
monitoring could also be useful for tracking
gut health status in patients with inflammatory
bowel disease, detecting presymptomatic
changes, and reducing the need for more
invasive tests, such as endoscopy. Future ap-
proaches could combine diagnostic strains
for multiplexed sensing, perhaps through the
conditional production of antibody-labeled
phage that are tracked with a companion
device based on an inverse ELISA, where
phage-displayed antibodies would be detected
using antigen-functionalized gold nano-
particles in a lateral flow test.
Much like bacteriophage can be used for
their natural homing capabilities, bacteria can
be used to target their preferred in vivo
niches. Microorganisms that migrate to and
preferentially accumulate in tumors, due
to their low-oxygen content, local immune
suppression, irregular blood supply, and nu-
trient availability, can be synthetically modi-
fied to assess and report tumor status (52). In
one study, nonpathogenic commensal bacte-
ria were genetically modified to express
the luxCDABE operon, endowing them with
bioluminescent qualities (Fig. 2B) (53). After
injection into mice carrying s.c. xenograft tu-
mors, these strains, in conjunction with bio-
luminescent 3D optical tomography combined
with micro-CT scanning, were used to visual-
ize the malignant growths. To reach deeper
tissues in patients and even multiplex output,
next-generation systems could be extended to
the expression of protein-based contrast agents
(45, 54–56). Using heme-binding proteins
and other reporters from functional mag-
netic resonance imaging, future applications
could possibly report from deeper tissue,
using orthologous reporters for greater in-
formation retrieval.
In a recent study, probiotic bacteria
(termed, PROP-Z) engineered to express
both lacZ and the luxCDABE operon, were
used to target, visualize, and diagnose liver
metastasis (57). Importantly, the stability of
the synthetic circuitry within PROP-Z was
secured by using a dual-maintenance strategy
that included the expression of the Bacillus
subtilis alp7 gene (leading to filament pro-
duction that ensures equal plasmid segrega-
tion upon cell division) (58), as well as a
toxin–antitoxin system that forces the cell to
either maintain the plasmid or die (59). Oral
or i.v. delivery yielded preferential coloniza-
tion of liver or s.c. tumors, respectively,
allowing for bioluminescent imaging. Fur-
thermore, administration of a luciferin/
galactose conjugate led to its cleavage by β-gal
and the resulting release of luciferin into
circulation and subsequent clearance by the
kidney, allowing for detection and quanti-
fication in urine samples.
Mammalian Cell Hosts. The preceding
examples depict efforts in modifying pro-
karyotic cells for in vivo biosensing. However,
there is also vast potential in using mam-
malian cells for hosting synthetic gene net-
works to monitor and/or influence the in vivo
environment. For example, researchers have
described an alternative to the aforementioned
bacteria-based luxCDABE bioluminescent
imaging system by introducing (and opti-
mizing) the full lux cassette into mammalian
host cells and successfully demonstrating
in vivo imaging using a mouse model
(60). Along with a crucial advantage over
Fig. 2. Synthetic biology devices for in vivo diagnostics. (A) The CaspaseTracker: Cytoplasmic Gal4 (blue) is released
to the nucleus by apoptotic caspases (orange), where it activates RFP and FLP recombinase (violet star) expression,
leading to persistent GFP expression and enabling apoptosis/anastasis tracking (demonstrated in fruit flies).
(B) Engineered bacteria naturally home in on tumors and express their synthetic circuits, producing bioluminescence for
in situ tumor imaging. (C) The cell-type “classifier” compares endogenous expression levels of three “high” miRNAs (left)
and three “low” miRNAs (right) to a preset HeLa profile. If all of the high miRNAs are above the threshold, this profile
leads to RNAi silencing of the transactivator (rtTA; blue) of the output gene’s repressor (LacI; orange), allowing for
output expression (DsRed; red dots). If all of the low miRNAs are below the threshold, the output mRNA is not de-
graded via RNAi (demonstrated in cell culture). (D) High urate levels lead to tumor lysis syndrome and gout. A
prosthetic urate homeostasis system transports urate (red cogs) into the encapsulated cells via constitutive URAT1
(orange) expression, where it releases mUTS’s (blue) repression of smUox (violet), a secreted uricase that converts the
urate to renally secretable allantoin (red dots). (E ) Bacteria engineered to record mammalian gut microbiome exposure
events. The memory element (M), comprised of a bacteriophage lambda cI/cro (blue/orange) switch and containing a
lacZ reporter (violet), is toggled to the “on” (cro, lacZ ) state when the Trigger element (T) detects ATc (black cogs) and
TetR (green) repression of a second cro copy is released. The detection of ATc results in the expression of β-gal from
the lacZ gene, which is readily measured in fecal samples.
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platforms that use firefly luciferase or
marine aequorin-like proteins—there is
no need for exogenous substrate injection
before imaging because the expression
cassette produces all of the necessary
components for bioluminescence (61, 62)—
this concept does not entail infection with a
bacterial host carrying the synthetic circuit
while providing the means for real-time
monitoring in live animals.
Engineered gene networks hosted in
mammalian cells could also serve as insulated
circuits that respond to exogenous input sig-
nals or “prosthetic” networks that autono-
mously sense the intra- or intercellular state,
enhancing endogenous pathways or endow-
ing cells with novel theranostic attributes
(63). In pioneering work that highlights this
potential, a prosthetic network comprised
of human, bacterial, and fungal parts was
designed for the control of urate homeostasis
(Fig. 2D) (64). The engineered cells were
encapsulated in mice for the treatment of
gout and tumor lysis syndrome, which results
from the formation of urate crystals in the
joints and kidneys, respectively. This system
was able to restore urate homeostasis through
detection of high urate levels and concomi-
tant derepression of a fungal urate oxidase, a
urate-metabolizing enzyme that has been lost
in humans (65, 66). Efforts continue to be
directed toward engineering dynamic mam-
malian circuits, including schemes that com-
bine drug-based and gene-based approaches.
In one such work, mammalian cells were
implanted with a synthetic signal cascade
that, when stimulated by an antihypertensive
drug (guanabenz), prompted two metaboli-
cally active peptides (GLP-1 and leptin) to be
secreted, in a multipronged strategy to com-
bat the metabolic syndrome (67).
Small regulatory RNAs offer an additional
mode of interaction between gene circuits
and host gene expression and physiology.
Just as metabolite levels can serve as in-
dicators of underlying health deficiencies and
be exploited to trigger corrective action, ex-
pression profiles can be used to drive syn-
thetic theranostic pathways. This concept
governs the cell-type “classifier”—an artificial
network that integrates sensory input from
microRNAs (miRNAs), discriminating be-
tween HeLa and non-HeLa cells (Fig. 2C)
(68). This network compares the expression
levels of six miRNAs to a preset HeLa profile
and computes whether to allow the expres-
sion of the output gene. The classifier serves
as an in vivo diagnostic or therapeutic, reg-
ulating the expression of a fluorescent re-
porter or proapoptosis gene, respectively.
RNA profiling networks that categorize bi-
ological state could prove invaluable for early
disease diagnosis and seem to be especially
well-suited for discriminating diseased cells
from self in cases of cancer, viral infections,
and autoimmune diseases.
Genetically encoded diagnostics can often
be repurposed to become therapeutics with a
simple molecular cloning step. This ability to
change the nature of the output is in stark
contrast to drug-based methods. With regard
to circuit-based treatments, a commonly de-
sired physiological response is gene-directed
cell death via the expression of cytotoxins,
siRNA, prodrug-associated enzymes, or nat-
ural apoptosis-linked genes. However, vari-
ous cancer cell lines in which apoptosis has
been induced may recover even after passing
critical checkpoints such as mitochondrial
fragmentation and nuclear condensation, if
the therapeutic agent is removed (69). Al-
though caspase-related apoptosis biosensors
for fluorescent imaging or immunodetection
have been explored, they lack the memory
capabilities required to report the recovery
from an apoptotic state (70). To diagnose
and record apoptosis and anastasis (its re-
versal), an in vivo CaspaseTracker biosensor
system was developed, whose function begins
with the apoptosis-induced, caspase-medi-
ated cleavage of a cytoplasmic Gal4 trans-
activator, followed by its translocation into
the nucleus (Fig. 2A) (71). There, it activates
the immediate expression of red fluorescent
protein (RFP) and also that of a flippase
(FLP) recombinase, for memory, leading to
the permanent expression of GFP that per-
sists throughout the life of the apoptotic/
anastatic cell’s progeny. This network, de-
veloped in Drosophila melanogaster, could be
applied to a mammalian research platform as
a tool to study apoptosis evasion tactics in the
context of cancer or even viral infection.
The majority of synthetic gene circuits are
based on networks regulated by transcription
factors (TFs); the first-generation circuits were
largely implemented with natural TFs (e.g.,
TetR, GAL4, or LacI) and their binding se-
quences (72). This limited repertoire has been
significantly expanded in recent years, with
the discovery and decoding of programmable
DNA-binding protein factors such as artificial
zinc fingers (ZFs), transcription activator-like
effectors, and the clustered regularly inter-
spaced short palindromic repeats/Cas system
(73). Today, one can target specific sequences
in natural and synthetic networks and deliver
activities ranging from transcriptional activa-
tion/repression to gene editing depending
on the functional component fused to the
DNA sensing domain (e.g., KRAB, VP64, or
Fok I endonuclease) (74). These important
developments have created a powerful driving
force toward genome editing and the wiring
of synthetic circuits that help elucidate the
function of their natural counterparts (75, 76).
Despite these advances, rationally designed
DNA-binding proteins have not reached
their potential regarding sensing capabilities.
For example, in most current applications,
designer DNA-binding proteins act upon the
DNA target itself (e.g., regulation/editing).
However, their programmability could also
be wielded to recognize pathogenic or onco-
genic sequences and drive an amplified re-
porter signal or a transcriptional response
originating from a separate endogenous or
synthetic locus. For example, although anti-
retroviral therapy can suppress viral loads
in patients infected with HIV-1, provirus
integrated into the genomes of quiescent
CD4+ T cells can reemerge upon cessation of
treatment (77). DNA-sensing proteins could
be designed to detect and report the presence
and location of such latent viral reservoirs. ZF
pairs fused to split β-lactamase have been
applied for in vitro sequence identification
(78), and this general concept could perhaps be
expanded upon for the in vivo environment.
Linking sequence detection to a customizable
transcriptional output might provide a way to
tailor a response for a desired physiological
outcome, such as immune system recruitment
or the activation of a kill switch that induces
apoptosis. This approach could yield a
powerful platform for identifying and com-
bating pathogen infection or oncogenic
transformation in vivo, and for endowing
mammalian cells with sentinel capabilities
for use in a bioreactor setting.
Delivery Challenges. The targeted delivery
of genetically encoded tools is a challenge
that surpasses that of drug delivery because
the cargo needs to reach its destination and
undergo expression. One of the earliest and
still major strategies used for delivery in-
volves virus-based vectors, including retro-
viruses, adenoviruses, and adeno-associated
viruses, which have been modified to carry
engineered payloads and cell-targeting
elements (79, 80). Self-assembled virus-like
particles (VLPs) and virosomes (virion-like
phospholipid bilayer vesicles with surface
glycoproteins) can also carry biomolecular
cargo (81, 82). Such delivery modes are quite
promising, and some have been approved for
use in humans. However, biosafety concerns
related to human viruses persist and extend
to VLPs and virosomes, in which immuno-
genicity may yet be an issue.
Some methods circumvent the need for
targeted delivery and rather rely on the in-
jection and diffusion of harmless biomarkers
for point-of-care diagnosis. A recently pub-
lished tool for the diagnosis of thrombosis
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and colorectal cancer exploits the disease-
related presence of specific endogenous
proteases, which cleave injected synthetic
biomarkers mounted on nanoparticles, free-
ing the reporter elements that are then read
via urinalysis (83). This concept could be
applied to limited-resource settings or even
adapted to serve as a readout for in vivo di-
agnostic gene circuits. In other recent work
involving point-of-care diagnosis, researchers
engineered bacteria to serve as biosensors
for the analysis of clinical urine or serum
samples to detect disease indicators, such as
nitrogen oxides and glucose (84). The “bac-
tosensors,” which contained integrase-based
synthetic circuitry that allowed for digi-
tization and recording of the pathological
markers, were embedded in hydrogel beads
and reliably detected glucose content in-
dicative of diabetes in urine samples from
multiple prediagnosed patients.
Targeted delivery is nonetheless required in
most in vivo theranostic approaches, and
nanobiotechnology offers a wealth of oppor-
tunities for the delivery of synthetic biology
devices. For example, researchers have de-
scribed DNA-based “nanorobots” that were
folded into 3D barrels and outfitted with
DNA aptamer-based locks for cell type-
specific cargo delivery (85). Only cell type-
specific surface antigen “keys” can unlock the
barrel, which then spills its contents like an
entropic spring, labeling the target cell or
influencing its signaling pathways. Although
there is great potential for such tools, the
in vivo susceptibility of DNA-based nano-
robots to degradation must be addressed
before use in humans; but, encouragingly,
nanorobots have been successfully demon-
strated in live insects (86). Solutions to resolve
degradation issues have been drawn from the
architecture of membrane-encapsulated viru-
ses, with lipid bilayer-coated DNA nano-
structures displaying dramatically increased
in vivo half-life (87). Nanorobots could
perhaps be conjugated to flagellated bacteria
and “rafted” to targeted tissues via bacterial
self-propulsion, similar to a recent study in
which the natural tumor-homing ability of
Salmonella typhimuria was exploited for the
delivery of attached, fluorescently labeled
microbeads (88). These “bacteriobots” were
injected into tumor-harboring mice and were
shown to accumulate in the cancerous tissue.
Biological vesicles derived from microor-
ganisms or human cells have also attracted
much attention for in vivo delivery and hold
promise for synthetic biology applications
(89). One recent study focused on outer
membrane vesicles (OMVs) that are natu-
rally produced by Gram-negative bacteria
(90). OMVs were engineered to display an
antibody targeting a receptor that is overex-
pressed in many malignant tumors and then
loaded with fluorescently labeled kinesin-
spindle-protein siRNA. Injection into a
mouse tumor model allowed for both growth
inhibition and in situ fluorescent imaging
of the xenograft. A similar delivery option,
exosomes (membrane vesicles secreted by
mammalian cells), may be even more ad-
vantageous over nonbiological materials be-
cause they can be produced from a patient’s
own cells (lower immunogenicity), and their
fusion with target-cell membrane may bypass
the endosomal–lysosomal pathway and avoid
inflammasome activation (91). Engineered
exosomes have been applied in both diag-
nostic and therapeutic applications, including
mouse models for cancer and Alzheimer’s
disease (92, 93). Looking forward, lipid-based
vesicles hold the exciting possibility of be-
coming bio-manufacturing products. For
now, vesicles must be loaded postproduction,
but it is exciting to consider future avenues in
which cell lines will be engineered for auto-
mated preloading of the cargo and diagnostic
capabilities.
Conclusions and Future Directions
As synthetic biology joins ranks with other
medical and scientific fields to tackle global
challenges, such as providing low-cost, rap-
idly deployable diagnostics, success will con-
tinue to be found at the interfaces between
disciplines. One example may include the
use of technology to augment gene circuits,
like the toehold switch, with hardware. As
discussed here, the engineering approaches of
synthetic biology have the potential to sig-
nificantly advance the translation of promis-
ing technologies into pragmatic tools suitable
for real-world applications. The paper-based
platform is poised to play a prominent role in
in vitro applications because it fits the need
for low-cost, practical, and simple diagnostic
tools for use outside of the laboratory, and the
underlying concept may be merged with
other technologies and extended in new and
exciting directions. Additionally, existing in
vivo sensors will begin to transition from their
current research models to patient applica-
tions for real-time monitoring and early,
personalized diagnosis. It is also intriguing
to imagine in vitro synthetic biology em-
bedded into diagnostic wearables for pa-
tients, medical personal, military personal or
even athletes, allowing for both personal and
environmental sensing. Bio-based wearables
could also serve as an interface for in vivo
diagnostics, alerting patients with preexisting
conditions to presymptomatic changes in
physiology. Ultimately, it will be the creativity
embodied in collaborative synthetic biology
that will guide this field into the future.
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